Q-omics provides the consensus-scored CBX3P6 profile across patient tissues and cancer cell-line models. CBX3P6 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CBX3P6 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, CBX3P6 RNA expression shows 6,547 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LUSC, and TGCT as cancer lineages where CBX3P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX3P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX3P6 survival associations across molecular data types. CBX3P6 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX3P6 RNA expression–survival associations across cancer types. High CBX3P6 expression shows unfavorable associations in COAD, KIRP, KIRC, STAD, LIHC and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CBX3P6 RNA expression.
This table summarizes CBX3P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CBX3P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX3P6 shows higher tumor expression in LUSC, LIHC and BRCA. The LUSC box plot shows higher CBX3P6 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .006).
This table shows molecular features associated with CBX3P6 in patient tissues and cancer cell lines. In patient samples, CBX3P6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
